Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis

Hardwick, Richard; Barham, C. P.; Ozua, Peter; Newcomb, Paul V.; Savage, Paul B.; Powell, Roy; Rahamin, J.; Alderson, Derek

doi:10.1016/s0748-7983(97)80139-4

Cited by 67 publications

(45 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This has been well established in previous studies conducted with nearly the same immunohistochemical procedures, together with a lack of correlation to prognosis, which is consistent with our findings (Sarbia et al, 1994;Hardwick et al, 1997;Shimada et al, 1999;Wang et al, 1999;Ahn et al, 2002;Rosa et al, 2003). P53 mutations are Diffuse EGFR staining and reduced overall survival L Gibault et al peculiarly frequent in high-SCCO incidence areas like Brittany (Audrezet et al, 1993), where we performed our study; some geographic specificity might also be implicated.…”

Section: P53 Protein In Sccosupporting

confidence: 92%

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

et al. 2005

View full text Add to dashboard Cite

Squamous cell carcinoma of the oesophagus (SCCO) is still a pathology of bad prognosis. Specific therapies are now developed against epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2, c-kit receptor (CD117), vascular endothelial growth factor (VEGF) and p53 protein. This study was aimed at assessing their expression in a large series of SCCO, as well as their potential therapeutic interest in this pathology. Immunohistochemical expression of these factors was assessed retrospectively in 107 cases of SCCO with primary surgery, as well as their relationships to recurrence, metastasis and overall survival on a long-term follow-up. Human epidermal growth factor receptor 2 and CD117 were expressed in less than 3% of the cases. Epidermal growth factor receptor and p53 were overexpressed in 68.2 and 66.4% of the cases, and VEGF in 38.3%. Epidermal growth factor receptor overexpression was significantly related to vascular invasion (P ¼ 0.023). Its diffuse positivity was significantly related in multivariate analysis to higher local recurrence (P ¼ 0.006) and lower overall survival (P ¼ 0.003), in a subgroup of patients of poor outcome who had received postoperative adjuvant treatment. These results highlight the great potential prognostic and therapeutic interest of evaluating EGFR diffuse positivity in locally advanced SCCO.

show abstract

Section: P53 Protein In Sccosupporting

confidence: 92%

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Thirdly, oesophageal SCC patients with both HLA-A24-and HER-2-positive tumours (1 þ / 2 þ /3 þ ) accounted for 26% of these cases, and both HLA-A2-and HER-2-positive tumours accounted for 18% of them. The frequencies of HER-2 overexpression in oesophageal SCC analysed by IHC ranged from 0 to 55.9% (Mori et al, 1987 HER-2 in oesophageal squamous cell carcinoma K Mimura et al Suo et al, 1992Suo et al, , 1995Shiga et al, 1993;Suwanagool et al, 1993;Lam et al, 1998;Hardwick et al, 1997;Akamatsu et al, 2003). Furthermore, reports describing HER-2 gene amplification ranged from 0 to 25%, in which these studies were performed by Northern blot, slot blot or RT -PCR analysis (Shiga et al, 1993;Ikeda et al, 1996;Tanaka et al, 1997;Friess et al, 1999).…”

Section: Discussionmentioning

confidence: 99%

“…With respect to oesophageal SCC, the frequencies of HER-2 overexpression analysed by immunohistochemistry (IHC) ranged from 0 to 55.9% (Mori et al, 1987;Chang et al, 1992;Suo et al, 1992;Shiga et al, 1993;Suwanagool et al, 1993;Suo et al, 1995;Hardwick et al, 1997;Lam et al, 1998;Akamatsu et al, 2003). Furthermore, reports describing HER-2 gene amplification ranged from 0 to 25%, and these studies were performed by Northern blot, slot blot or RT -PCR analysis (Shiga et al, 1993;Ikeda et al, 1996;Tanaka et al, 1997;Friess et al, 1999).…”

mentioning

confidence: 99%

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma

et al. 2005

View full text Add to dashboard Cite

The utilisation of antitumour T cells induced by cancer vaccination with HER-2 peptides or antibodies (Herceptin) against HER-2, as immunotherapy for oesophageal cancer, is a novel and attractive approach. It is important to clarify the frequencies of HER-2 expression and gene amplification in patients with oesophageal squamous cell carcinoma (SCC) and to evaluate the relationship between HER-2 status and HLA haplotype, since the candidates for HER-2 peptide-based vaccination are restricted to a certain HLA haplotype. We determined the frequency of HER-2 expression using the HercepTestt for immunohistochemistry and HER-2 gene amplification by fluorescence in situ hybridisation (FISH) assay in oesophageal SCC (n ¼ 66). HER-2-positive tumours (1 þ /2 þ /3 þ ) analysed by a HercepTest were observed in 30.3% of all the patients and HER-2 gene amplification evaluated by FISH was observed in 11.0% of all the patients, in which all HercepTest (3 þ ) tumours were found to have gene amplification and three of six moderately positive (2 þ ) tumours showed gene amplification. Furthermore, HER-2-positive cells were present more diffusely and were larger within each tumour in the patients who were HercepTest 3 þ than those who were HercepTest 1 þ . Moreover, the survival rate in HER-2-positive group was significantly worse than that in HER-2-negative group. Also, the survival rate in the patients with HER-2 gene amplification was significantly worse than that without HER-2 gene amplification. In addition, oesophageal SCC patients with both HLA-A24-positive and HER-2-positive tumours (1 þ /2 þ /3 þ ) accounted for 26% of these cases, and both HLA-A2-and HER-2-positive tumours accounted for 18% of them.

show abstract

“…Overexpression of EGFR has been reported in a number of human cancers, including esophageal squamous cell carcinoma (1,2). By contrast, ErbB2 overexpression has been noted in approximately 10-25% of human esophageal carcinomas (2)(3)(4), but this does not extend to ErbB3 and ErbB4 (5). EGFR overexpression is often associated with increased production of ligands, which bind EGFR, thereby creating an autocrine loop, which facilitates tumor growth (6).…”

mentioning

confidence: 99%

Akt/Protein Kinase B Isoforms Are Differentially Regulated by Epidermal Growth Factor Stimulation

Okano¹,

Gaslightwala²,

Birnbaum³

et al. 2000

Journal of Biological Chemistry

189

147

View full text Add to dashboard Cite

Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis

Cited by 67 publications

References 57 publications

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma

Akt/Protein Kinase B Isoforms Are Differentially Regulated by Epidermal Growth Factor Stimulation

Contact Info

Product

Resources

About